Next-gen RNAi drugmaker City prices $200M IPO
Next-gen RNAi drugmaker City prices $200M IPO
City Therapeutics
Private
City Therapeutics is a clinical-stage biotechnology company pioneering next-generation RNA interference (RNAi) medicines, founded by John Maraganore (former CEO of Alnylam Pharmaceuticals) and a team of RNAi pioneers. The company's lead platform is based on cleavage-inducing tiny guide RNAs (cityRNAs) designed to improve potency and durability over first-generation siRNA therapeutics, with three programs in the pipeline targeting cardiometabolic and rare diseases.
Company Info
Sector:Biotechnology / RNA Therapeutics
Headquarters:Cambridge, Massachusetts, USA
Founded:2023
Website:www.citytx.com/
Funding Round:$99M financing (June 2026) to advance three RNAi programs into the clinic
Total Funding:$99M disclosed (June 2026 round)
Funding & Investor Relations
IPO Outlook / Plans
None publicly disclosed; private RNAi platform company focused on pipeline development.
Upcoming Milestones & Key Dates
H2 2026
Regulatory
First IND filing for CTX-001 cardiometabolic program
Late 2026 / 2027
Business Development
Pipeline expansion update and potential Series B or strategic partnership
Clinical Development Pipeline
CTX-001 (cityRNA lead program)
Target: Cleavage-inducing tiny guide RNA (cityRNA) targeting validated geneCTX-002 (cityRNA program)
Target: cityRNA targeting tissue-specific geneCTX-003 (cityRNA program)
Target: cityRNA targeting CNS/ocular geneRecent News
RNAi biotech City hauls in $200m in upsized IPO
City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference therapies headed by a novel anticoagulant.
City’s IPO soars to $200M, with proceeds supporting thromboembolic disease pipeline
City Therapeutics will join a slew of biotechs that have entered the public markets this year, with a $200 million raise that landed above expectations.
City Therapeutics files for US IPO as biotech listings surge
City Therapeutics files for US IPO as biotech listings surge
City Therapeutics Gets $99M to Gather Data on Three RNAi Medicines
City Therapeutics has closed a $99M financing round to advance its pipeline of three RNAi medicines, betting on a next-generation small interfering RNA platform that aims to improve potency and durability over current standards.
Leadership Team
John Maraganore
Founder and Chief Executive Officer (former CEO of Alnylam Pharmaceuticals)